Wave Life Sci Ord Sh (WVE) Stock Price, Quote & News

Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of...

Industry: Biotechnology

Sector: Healthcare

Phone: 65 6236 3388

Website: wavelifesciences.com

Address:

Marina One East Tower, 7 Straits View No.12-00, Singapore, Singapore

collegeballer48 May. 12 at 7:03 PM

$WVE just when you thought the floor was $7

0 · Reply

ScorpionScarlet May. 12 at 5:32 PM

$WVE interesting action. May re-visit. 🥳💕💸

0 · Reply

PanP May. 12 at 2:49 PM

$WVE This turd is about to lose another investor. Waitng is one thing, losing money while you wait is bullshit

0 · Reply

Hankjessie May. 8 at 12:28 PM

$WVE own WVE, ALT, VKTX all pretty big. As soon as one gets taken out, I sell the other two pigs. Opportunity cost is mind blowing.

0 · Reply

BB_88_ May. 7 at 10:47 PM

$WVE will she break out 🤷‍♂️

1 · Reply

PepCF May. 7 at 5:41 PM

$WVE Hoping my patience following RA Capital finally pays off sooner rather than later.

0 · Reply

collegeballer48 May. 5 at 3:36 PM

$WVE this stock can’t hold $7.50 to save its life.

1 · Reply

rombrento May. 1 at 5:48 PM

$WVE

0 · Reply

PenkeInvesting May. 1 at 1:25 PM

Fundamental analysis of $WVE (Wave Life Sciences Ltd.) based on financial data and reported results. #WVE

0 · Reply

Autolus_Freakk Apr. 30 at 8:51 AM

$WVE what's the next catalyst?

1 · Reply

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference

2026-05-04T11:00:31.000Z - 9 days ago

Wave Life Sciences price target lowered to $24 from $30 at Citi

2026-04-30T13:11:32.000Z - 13 days ago

Wave Life Sciences price target lowered to $43 from $52 at Canaccord

2026-04-29T12:23:04.000Z - 14 days ago

Wave Life Sciences price target lowered to $19 from $21 at BofA

2026-04-29T09:10:14.000Z - 14 days ago

Wave Life Sciences assumed with a Buy at Truist

2026-04-28T16:35:16.000Z - 15 days ago

Wave Life Sciences price target lowered to $36 from $39 at Clear Street

Apr 28, 2026, 8:30 AM EDT - 15 days ago

Wave Life Sciences Earnings Call Transcript: Q1 2026

2026-04-28T11:59:24.000Z - 15 days ago

Wave Life Sciences reports Q1 EPS (13c), consensus (31c)

Apr 28, 2026, 7:30 AM EDT - 15 days ago

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 22, 2026, 8:30 AM EDT - 21 days ago

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

2026-04-21T20:05:17.000Z - 22 days ago

Wave Life Sciences announces hearing on proposed redomicilation

Apr 21, 2026, 4:01 PM EDT - 22 days ago

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Apr 15, 2026, 4:01 PM EDT - 4 weeks ago

Wave Life Sciences Announces Proposed Redomiciliation to the United States

2026-04-14T10:21:03.000Z - 4 weeks ago

Wave Life Sciences price target lowered to $18 from $30 at H.C. Wainwright

2026-04-07T15:06:37.000Z - 5 weeks ago

Wave Life Sciences price target lowered to $15 from $27 at RBC Capital

2026-03-27T12:11:34.000Z - 6 weeks ago

Wave Life Sciences removed from Best Ideas List at Wedbush

2026-03-27T10:40:43.000Z - 6 weeks ago

Wave Life Sciences price target lowered to $21 from $38 at BofA

2026-03-27T10:30:44.000Z - 6 weeks ago

Wave Life Sciences price target lowered to $13 from $27 at Wells Fargo

2026-03-26T20:26:07.000Z - 6 weeks ago

Wave Life Sciences price target lowered to $39 from $50 at Clear Street

2026-03-26T19:35:42.000Z - 6 weeks ago

Wave Life Sciences price target lowered to $25 from $35 at Leerink

Mar 26, 2026, 3:00 PM EDT - 6 weeks ago

Wave Life Sciences stock crash: why analyst sees a buying opportunity

2026-03-26T18:11:25.000Z - 6 weeks ago

Wave Life Sciences price target lowered to $18 from $28 at Jefferies

Mar 26, 2026, 10:28 AM EDT - 6 weeks ago

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 26, 2026, 9:33 AM EDT - 6 weeks ago

Wave Life Sciences shares plunge as data for high dose of obesity drug disappoints

Mar 26, 2026, 8:30 AM EDT - 6 weeks ago

Wave Life Sciences Transcript: Study result

Mar 26, 2026, 7:30 AM EDT - 6 weeks ago

Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007

Mar 6, 2026, 11:33 AM EST - 2 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA RGNX

Mar 5, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Feb 26, 2026, 2:40 PM EST - 2 months ago

Wave Life Sciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences Earnings Call Transcript: Q4 2025

Feb 26, 2026, 7:30 AM EST - 2 months ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 23, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 8:30 AM EST - 2 months ago

Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

Feb 2, 2026, 7:30 AM EST - 3 months ago

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Jan 13, 2026, 5:15 PM EST - 4 months ago

Wave Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 4 months ago

Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio

Jan 5, 2026, 8:30 AM EST - 4 months ago

Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:30 AM EST - 5 months ago

Why Did Wave Life Sciences Surge 147%?

Dec 9, 2025, 9:50 PM EST - 5 months ago

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 5 months ago

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 8, 2025, 8:30 AM EST - 5 months ago

Wave Life Sciences Transcript: Study Update

Dec 8, 2025, 7:30 AM EST - 5 months ago

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Dec 7, 2025, 4:00 PM EST - 5 months ago

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

Nov 20, 2025, 4:00 AM EST - 6 months ago

Wave Life Sciences Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 10:00 AM EST - 6 months ago

Wave Life Sciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

Wave Life Sciences Earnings Call Transcript: Q3 2025

Nov 10, 2025, 7:30 AM EST - 6 months ago

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 8:30 AM EST - 6 months ago

Wave Life Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:30 PM EST - 6 months ago

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Nov 4, 2025, 8:30 AM EST - 6 months ago

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

Oct 29, 2025, 10:50 PM EDT - 6 months ago

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 4:15 PM EDT - 7 months ago

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Oct 29, 2025, 10:00 AM EDT - 7 months ago

Wave Life Sciences Transcript: Research Day

Oct 21, 2025, 1:00 PM EDT - 7 months ago

Wave Life Sciences Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Sep 30, 2025, 1:00 PM EDT - 8 months ago

Wave Life Sciences Transcript: Stifel Virtual Cardiometabolic Forum

Sep 24, 2025, 2:50 PM EDT - 8 months ago

Wave Life Sciences Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 18, 2025, 8:30 AM EDT - 8 months ago

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

Sep 3, 2025, 8:30 AM EDT - 9 months ago

Wave Life Sciences Transcript: Status Update

Sep 3, 2025, 7:30 AM EDT - 9 months ago

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Jul 30, 2025, 8:30 AM EDT - 10 months ago

Wave Life Sciences Earnings Call Transcript: Q2 2025

Jul 30, 2025, 7:30 AM EDT - 10 months ago

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 8:30 AM EDT - 10 months ago

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Jun 20, 2025, 4:01 PM EDT - 11 months ago

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Wave Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:30 AM EDT - 1 year ago

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 8, 2025, 8:30 AM EDT - 1 year ago

Wave Life Sciences Earnings Call Transcript: Q1 2025

May 8, 2025, 7:30 AM EDT - 1 year ago

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:30 AM EDT - 1 year ago

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

Mar 26, 2025, 8:30 AM EDT - 1 year ago

Wave Life Sciences Transcript: Study Result

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

Mar 4, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Earnings Call Transcript: Q4 2024

Mar 4, 2025, 7:30 AM EST - 1 year ago

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Jan 13, 2025, 12:45 PM EST - 1 year ago

Wave Life Sciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 23, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Dec 16, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:00 PM EST - 1 year ago

Wave Life Sciences Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 3:00 PM EST - 1 year ago

Wave Life Sciences Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 20, 2024, 11:30 AM EST - 1 year ago

Wave Life Sciences Transcript: Jefferies London Healthcare Conference 2024

Nov 15, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Nov 12, 2024, 8:30 AM EST - 1 year ago

Wave Life Sciences Earnings Call Transcript: Q3 2024

Oct 30, 2024, 4:45 PM EDT - 1 year ago

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Wave Life Sciences Transcript: Status Update

Oct 16, 2024, 8:25 AM EDT - 1 year ago

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Oct 1, 2024, 1:00 PM EDT - 1 year ago

Wave Life Sciences Transcript: Chardan's 8th Annual Genetic Medicines Conference

Oct 1, 2024, 9:20 AM EDT - 1 year ago

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Sep 25, 2024, 9:14 PM EDT - 1 year ago

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Sep 24, 2024, 4:01 PM EDT - 1 year ago

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

collegeballer48 May. 12 at 7:03 PM

$WVE just when you thought the floor was $7

0 · Reply

ScorpionScarlet May. 12 at 5:32 PM

$WVE interesting action. May re-visit. 🥳💕💸

0 · Reply

PanP May. 12 at 2:49 PM

$WVE This turd is about to lose another investor. Waitng is one thing, losing money while you wait is bullshit

0 · Reply

Hankjessie May. 8 at 12:28 PM

$WVE own WVE, ALT, VKTX all pretty big. As soon as one gets taken out, I sell the other two pigs. Opportunity cost is mind blowing.

0 · Reply

BB_88_ May. 7 at 10:47 PM

$WVE will she break out 🤷‍♂️

1 · Reply

PepCF May. 7 at 5:41 PM

$WVE Hoping my patience following RA Capital finally pays off sooner rather than later.

0 · Reply

collegeballer48 May. 5 at 3:36 PM

$WVE this stock can’t hold $7.50 to save its life.

1 · Reply

rombrento May. 1 at 5:48 PM

$WVE

0 · Reply

PenkeInvesting May. 1 at 1:25 PM

Fundamental analysis of $WVE (Wave Life Sciences Ltd.) based on financial data and reported results. #WVE

0 · Reply

Autolus_Freakk Apr. 30 at 8:51 AM

$WVE what's the next catalyst?

1 · Reply

LiveCommander Apr. 30 at 1:16 AM

$ALEC pulling the plug on PROGRESS-AD Phase 2 for nivisnebart after interim futility hit. Another progranulin shot at early Alzheimer's that just didn't move the needle. GSK partnership value takes a real hit here. Cash runway and FTD program $WVE become the whole story now. Brutal print 📉

0 · Reply

PepCF Apr. 29 at 2:33 PM

$WVE Whenever I see red on the screen, I just remind myself that RA Capital loaded up on $54.6M worth of shares

0 · Reply

collegeballer48 Apr. 29 at 11:31 AM

$WVE this stock is pinned around the $7.30s. ER was better than expected, phase 2 confirmed, and it still can’t hold above $7.50.

0 · Reply

BioRich Apr. 28 at 12:30 PM

$WVE let's move higher!

0 · Reply

PepCF Apr. 28 at 12:13 PM

$WVE

0 · Reply

DARKP00L Apr. 28 at 12:06 PM

$WVE 07:36 on Apr. 28 2026 Wave Life Sciences Reports Cash And Cash Equivalents Of $544.6M As Of March 31, 2026, With Expected Cash Runway into Q3 2028 #tradeideas

0 · Reply

StocktwitsEarnings Apr. 28 at 11:39 AM

$WVE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.13 up 55.17% YoY • Reported revenue of $38.25M up 316.85% YoY • Wave Life Sciences expects its current cash and cash equivalents to fund operations into the third quarter of 2028. The company is on track to initiate the Phase 2a portion of the INLIGHT trial in 2Q 2026.

0 · Reply

SuperGreenToday Apr. 27 at 10:04 PM

$WVE Share Price: $6.93 Contract Selected: Oct 16, 2026 $5 Calls Buy Zone: $1.87 – $2.31 Target Zone: $3.29 – $4.02 Potential Upside: 66% ROI Time to Expiration: 171 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

collegeballer48 Apr. 27 at 5:33 PM

$WVE unless ER is a surprise tomorrow we could take another nose dive. GLTA

0 · Reply

BioRich Apr. 27 at 2:26 PM

$ADMA $AVXL $WVE $IBRX $GUTS I'd say we're looking pretty good on this one. $GUTS is a must have in ANY account. Set it and forget it. My #1 pick (Bio or otherwise). Follow/Subscribe for more winners and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

free2dream Apr. 26 at 8:48 PM

$WVE how the fxck is this at 7 bucks and $SRPT at 19 ? ABSOLUTELY IDIOTIC ! AI and SEMIS HYPE , one sided and extremely crowded trade while rest of the market trades like shit

0 · Reply

PepCF Apr. 24 at 7:23 PM

$WVE Adding to the position

0 · Reply

Market Cap	1.36B
Revenue (ttm)	42.73M
Net Income (ttm)	-204.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-478.31%
Debt to Equity Ratio	0.00

Volume	7,283,589
Avg Vol	4,805,846
Day's Range	N/A - N/A
Shares Out	192.40M
Stochastic %K	2%
Beta	-1.32
Analysts	Strong Sell
Price Target	$23.60